Role of proteoglycans in renal chronic transplant dysfunction
PhD ceremony: Mr. K.K. Katta, 12.45 uur, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Role of proteoglycans in renal chronic transplant dysfunction
Promotor(s): prof. G.J. Navis, prof. J.L. Hillebrands
Faculty: Medical Sciences
Kidney transplantation is the best treatment for patients with end stage renal failure, in terms of quality of life and life expectancy. Chronic transplant dysfunction (CTD) is associated with decline in kidney function over time and is related to progressive tissue remodeling in the transplanted kidney. Proteoglycans (PGs) have been highly implicated in tissue remodeling such as development, adhesion, migration, growth, wound healing and repair processes, proliferation and fibrosis. This implies that targeting proteoglycan function might provide a strategy to combat CTD-associated tissue remodeling. The data presented in this thesis show the involvement of PGs in CTD tissue remodeling. We showed an upregulation of the heparan sulfate PGs collagen type XVIII and perlecan and chondroitin sulfate PG versican in rat renal allografts. The binding properties of the upregulated PGs has increased upon renal allotransplantation. Perlecan and FGF2 were found to be upregulated in renal allografts. The functional and mechanistical roles of these PGs were studied in vitro using rat glomerular mesangial cells. The results showed that PGs mediated FGF2-dependent proliferation of mesangial cells. Treatment with non-anti-coagulant heparin (RO-heparin) showed beneficial effects after rat renal transplantation. Considering the molecular mechanisms behind neointima formation, we showed that in response to allogeneic transplantation there will be medial dedifferentiation, probably mediated by PDGF-B. Lastly we showed that syndecan-1, a trans-membrane cell surface heparan sulfate PG, is involved in tubular regeneration and repair after renal transplantation and ischemia/reperfusion which correlated with better graft function and survival. Overall PGs are crucially involved in tissue remodeling after transplantation and promising intervention molecules to retard CTD.
Last modified: | 13 March 2020 01.01 a.m. |
More news
-
16 January 2025
€16,5 miljoen subsidie voor onderzoek naar effect CAR T-cellen bij terugkerende beenmergkanker
Het UMCG gaat specifieke CAR-T cellen produceren om patiënten met terugkerende beenmergkanker te behandelen. Samen met Amsterdam UMC Cancer Center Amsterdam gaat het UMCG de effectiviteit van deze mogelijk nieuwe behandeling onderzoeken. Voor het...
-
16 December 2024
Jouke de Vries: ‘The University will have to be flexible’
2024 was a festive year for the University of Groningen. Jouke de Vries, the chair of the Executive Board, looks back.
-
27 August 2024
UMCG gaat onderzoeksfaciliteiten beschikbaar stellen voor geneesmiddelenontwikkeling
Om de beschikbaarheid en effectiviteit van geneesmiddelen in Nederland te verbeteren gaat het UMCG het bedrijf G² Solutions opzetten. Dit bedrijf moet ervoor gaan zorgen dat belangrijke technologische ontwikkelingen op het gebied van DNA sequencing...